Treatment
Cell clinical trials
We’re tracking 5,710 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06734832RecruitingPhase 3
Vaccine trial for hand, foot, and mouth disease
This trial tests a new two-in-one vaccine to protect children against hand, foot, and mouth disease caused by two common viruses (EV71 and CA16). It is for healthy kids ages 6 months to 5 years and will check if the vaccine is safe and works well.
Hefei, AnhuiAges 6 months–5.9 years - NCT06734871RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06735690RecruitingEarly Phase 1
Immune cells plus vaccine after stem cell transplant for leukemia
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Duarte, CaliforniaAges 18 years+ - NCT06755684RecruitingPhase 2
Pre-surgery targeted drug combo for EGFR-mutant lung cancer
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06765317RecruitingPhase 2
Glofitamab therapy for older adults with diffuse large B-cell lymphoma
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
Basking Ridge, New JerseyAges 65–80 - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT06768905RecruitingPhase 1/Phase 2
Radiation followed by CAR-T cells for relapsed/refractory DLBCL
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
Dallas, TexasAges 18 years+ - NCT06784167Recruiting
Vaccine response after CAR-T for myeloma and lymphoma
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Portland, OregonAges 18 years+ - NCT06785077Recruiting
Genetic Study in Ovarian Cancer During PARP Inhibitor Therapy
This study looks at the genetic changes in ovarian cancer cells before and during treatment with PARP inhibitors. It aims to understand how these changes may affect treatment response.
MilanAges 18 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06793410RecruitingPhase 2
HPV vaccine after stem cell transplant
This trial tests if the HPV vaccine works safely in people who received a stem cell transplant from a donor. It may help prevent HPV-related cancers in transplant survivors.
Lund, Region SkåneAges 18–45 - NCT06810778RecruitingPhase 1/Phase 2
Duvelisib plus venetoclax for relapsed PTCL
This study tests two oral drugs—duvelisib and venetoclax—to see if together they can help people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06815029RecruitingPhase 1
Modified immune cells for recurrent brain cancer
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT06822868RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT06826365Recruiting
Immune cells in the uterus and infertility
This study looks at immune cells inside the uterus to understand why some women have infertility or repeated miscarriages. You may join if you have had at least two miscarriages or certain benign gynecological conditions.
KrakowAges 18–45 - NCT06835140RecruitingPhase 1
NK cell immunotherapy for AML that has stopped responding to treatment
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
Beijing, ChinaAges 18–70 - NCT06836505RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed neuroblastoma and related tumors
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
Guangzhou, GuangdongAges 1–50 - NCT06839976RecruitingPhase 1/Phase 2
CART19 cell therapy for lupus in young people
This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.
Philadelphia, PennsylvaniaAges 12–29 - NCT06852638RecruitingPhase 2
PET imaging for kidney cancer, lymphoma, and NPC
This study tests a new way to detect tumors by using a special injection that makes cancer cells visible on a PET scan. It may help people with renal cancer (especially clear cell type), lymphoma, or nasopharyngeal cancer.
ShanghaiAges 18–80 - NCT06874946RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for relapsed T-cell leukemia or lymphoma
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
Beijing, Beijing MunicipalityAges 3–70 - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT06885476Recruiting
NK cell infusion for AML patients with minimal cancer left
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
Bologna, BOAges 18 years+ - NCT06889467Recruiting
Testing leftover fluid from lymph node biopsies to find lung cancer
This trial is for people who are scheduled for a lung cancer biopsy (EBUS-TBNA) because doctors suspect non-small cell lung cancer (NSCLC) has spread to lymph nodes. It will test leftover fluid from the biopsy to see if it improves cancer detection. If your biopsy is negative but you still need surgery to remove lymph nodes, you can help us learn more about this new test.
AshkelonAges 18 years+ - NCT06896747RecruitingPhase 1/Phase 2
Stem cell therapy for thin uterine lining
This trial tests a new treatment using stem cell particles (exosomes) to help rebuild the lining of the womb in women whose lining is too thin after surgery for scar tissue. It may improve chances of success with IVF.
Xi'an, ShaanxiAges 20–40
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,710 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.